Liminatus Pharma, Inc. Class A Common Stock
Liminatus Pharma, Inc. Class A Common Stock Fundamental Analysis
Liminatus Pharma, Inc. Class A Common Stock (LIMN) shows weak financial fundamentals with a PE ratio of -0.40, profit margin of 0.00%, and ROE of 2.16%. The company generates N/A in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 191.0/100 based on profitability, valuation, growth, and balance sheet metrics. The A grade reflects excellent fundamentals and strong overall stability.
Fundamental Health Score
We analyze LIMN's fundamental strength across five key dimensions:
Efficiency Score
WeakLIMN struggles to generate sufficient returns from assets.
Valuation Score
ExcellentLIMN trades at attractive valuation levels.
Growth Score
WeakLIMN faces weak or negative growth trends.
Financial Health Score
ModerateLIMN shows balanced financial health with some risks.
Profitability Score
WeakLIMN struggles to sustain strong margins.
Key Financial Metrics
Is LIMN Expensive or Cheap?
P/E Ratio
LIMN trades at -0.40 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, LIMN's PEG of -0.01 indicates potential undervaluation.
Price to Book
The market values Liminatus Pharma, Inc. Class A Common Stock at -33.55 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at -0.50 times EBITDA. This is generally considered low.
How Well Does LIMN Make Money?
Net Profit Margin
For every $100 in sales, Liminatus Pharma, Inc. Class A Common Stock keeps $0.00 as profit after all expenses.
Operating Margin
Core operations generate 0.00 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $2.16 in profit for every $100 of shareholder equity.
ROA
Liminatus Pharma, Inc. Class A Common Stock generates $-3.94 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
FCF Per Share
Each share generates $-0.50 in free cash annually.
FCF Yield
LIMN converts -2.38% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-0.40
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.01
vs 25 benchmark
P/B Ratio
Price to book value ratio
-33.55
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.00
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
-10.88
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.96
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
2.16
vs 25 benchmark
ROA
Return on assets percentage
-3.94
vs 25 benchmark
ROCE
Return on capital employed
38.36
vs 25 benchmark
How LIMN Stacks Against Its Sector Peers
| Metric | LIMN Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -0.40 | 28.87 | Better (Cheaper) |
| ROE | 215.73% | 743.00% | Weak |
| Net Margin | 0.00% | -49695.00% (disorted) | Weak |
| Debt/Equity | -10.88 | 0.38 | Strong (Low Leverage) |
| Current Ratio | 0.96 | 3.96 | Weak Liquidity |
| ROA | -394.33% | -21214.00% (disorted) | Weak |
LIMN outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Liminatus Pharma, Inc. Class A Common Stock's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation